Barrett R J, Turpin J A, McGuirk B A, Kau S T
Pharmacol Res Commun. 1985 Jan;17(1):49-61. doi: 10.1016/0031-6989(85)90051-7.
The renal pharmacological actions of the non-selective opioid receptor antagonist naloxone and the selective delta (delta)-opioid receptor antagonist ICI 154,129 were examined in conscious dogs. Neither naloxone nor ICI 154,129 altered glomerular filtration rate, renal blood flow, blood pressure, heart rate, or renal excretion of water, Na+, K+, or Cl-. In addition, urine and plasma osmolality and electrolyte concentrations and hematocrit were unchanged, suggesting that neither agent produced physiologically significant alteration in plasma vasopressin levels. These data suggest that (a) naloxone and ICI 154,129 exert no renal pharmacological effects in dogs and (b) under resting physiological conditions, delta-opioid receptors, as well as other opioid receptor subtypes, probably are not involved in the tonic regulation of renal hemodynamics or tubular function.
在清醒犬中研究了非选择性阿片受体拮抗剂纳洛酮和选择性δ(δ)-阿片受体拮抗剂ICI 154,129的肾脏药理作用。纳洛酮和ICI 154,129均未改变肾小球滤过率、肾血流量、血压、心率或水、钠、钾或氯的肾排泄。此外,尿和血浆渗透压、电解质浓度及血细胞比容均未改变,提示这两种药物均未引起血浆血管加压素水平发生具有生理学意义的改变。这些数据表明:(a)纳洛酮和ICI 154,129在犬中不产生肾脏药理作用;(b)在静息生理条件下,δ-阿片受体以及其他阿片受体亚型可能不参与肾血流动力学或肾小管功能的紧张性调节。